Investment analysts at StockNews.com started coverage on shares of SenesTech (NASDAQ:SNES – Get Free Report) in a research note issued to investors on Friday. The brokerage set a “sell” rating on the stock.
Separately, HC Wainwright reaffirmed a “buy” rating and issued a $35.00 price target on shares of SenesTech in a report on Tuesday, May 14th.
Read Our Latest Report on SenesTech
SenesTech Stock Down 3.4 %
SenesTech (NASDAQ:SNES – Get Free Report) last issued its quarterly earnings results on Thursday, August 8th. The company reported ($3.08) earnings per share for the quarter, topping analysts’ consensus estimates of ($3.20) by $0.12. The business had revenue of $0.46 million for the quarter, compared to analyst estimates of $0.49 million. SenesTech had a negative return on equity of 168.64% and a negative net margin of 464.09%. During the same quarter in the previous year, the firm earned ($84.03) earnings per share. Sell-side analysts anticipate that SenesTech will post -11 EPS for the current fiscal year.
SenesTech Company Profile
SenesTech, Inc develops a technology for managing animal pest populations through fertility control. It offers ContraPest, a liquid bait that limits reproduction of male and female rats. The company was incorporated in 2004 and is headquartered in Phoenix, Arizona.
Featured Stories
- Five stocks we like better than SenesTech
- Canadian Penny Stocks: Can They Make You Rich?
- Is Merck Stock Undervalued After Its Colossal Earnings Growth?
- When to Sell a Stock for Profit or Loss
- Top 5 ETFs for Every Investor: From Semiconductors to Defense
- 2 Fintech Stocks to Buy Now and 1 to Avoid
- Blade Air Mobility: This Under-the-Radar Stock Could Double Soon
Receive News & Ratings for SenesTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SenesTech and related companies with MarketBeat.com's FREE daily email newsletter.